Wooin Lee, Ph.D.

Associate Professor

Address

• E-mail: wooin.lee@snu.ac.kr
•Web Site : http://openwetware.org/wiki/Lee
•Tel : +82-2-880-7873/7878

Education

•Ph.D. University at Buffalo, SUNY, USA
•B.S., M.S. Seoul Nat'l Univ.

Work Experience

•2008 - 2014: Assistant & Associate Professor, Univ. of Kentucky, USA
•2004 - 2008: Research Assistant Professor, Vanderbilt University, USA
•2001- 2004: Postdoctoral research fellow, Vanderbilt University, USA

Selected Publications

• The N-terminal region of Organic Anion Transportin g Polypeptide 1B3 (OATP1B3) plays an essential rol e in regulating its plasma membrane trafficking. *Bio chem Pharmacol* (2017)
• Alternative splicing: Expanding diversity in major ABC and SLC drug transporters. *AAPS J* 19(6):1 643-1655 (2017)
• Inhibition of organic anion transporting polypeptide 1B1 and 1B3 by betulinic acid: Effects of pre- incu bation and albumin in the media. *J Pharm Sci* 107: 1713-1723 (2018)
• Next-generation proteasome inhibitors for cancer therapy. *Trans Res* 198:1-16 (2018)
• Physiologically based pharmacokinetic modeling of bosentan identifies the saturable hepatic uptake as a major contributor to its nonlinear pharmacokinetics. *Drug Metab Dispos* 46(5):740-748 (2018)
• Expanding therapeutic utility of carfilzomib for br east cancer therapy by novel albumin-coated nanoc rystal formulation. *J Controlled Rel* 302:148- 159 (2019)

Molecular Biopharmaceutics

The goal of our research is to better understand the genetic and molecular bas es for inter-individual variability in drug disposition and response/toxicity. Our o ngoing research focuses on the development of novel chemotherapeutic agent s/strategies by utilizing our understanding of drug metabolizing enzymes, trans porters and drug targets such as proteasomes.



I. Investigationof the impact of splicing & other genetic variations on drug transportersand proteasomes



II. Development of novel proteasome inhibitor drugs & delivery s trategies to improve anticancer efficacy & expand therapeutic utilities



III. Clinical Pharmacokinetics, Pharmacogenomics & Pharmaco metrics